#2885 DYNAMICS OF URINARY SYNDROME IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS DEPENDING ON THE USE OF ANTICOAGULANT

to study the dynamics of urinary syndrome in patients with chronic glomerulonephritis (CGN) against the background of the use of rivoroxaban.

108 patients with chronic glomerulonephritis (CGN), on the background of 3-month basic therapy with the inclusion of with anticoagulant rivaroxaban 55 patients and without anticoagulant 53 patient. Initially and after 3 months, the composition of the urinary sediment was assessed.

Patients with CGN had significant proteinuria (3.23±0.12g/l versus 0.01±0.004 control group (CG), p<0.001), hematuria (42.58±2.10 erythrocytes in the field of vision, against 0.75±0.25 cells in the field of vision, p<0.001), leukocyturia (38.25±0.80 leukocytes in the field of vision, against 1.70±0.24 cells in the field of view in CG, p<0.001) and cylindruria (38.11±1.04 cylinders in the field of view, versus 0.10±0.07 cylinders in the field of view in CG, p<0.001). Albuminuria contributed to an increase in the specific gravity of urine (1021.64±0.44 g/l versus 1017.45±0.65g/l in CG, p<0.001). By the end of the hospitalization period, there was a significant improvement in urinary syndrome: the relative dynamics of urinary syndrome indicators was more than 30%. Thus, the degree of proteinuria decreased to 1.98± 0.10 g/l (p<0.001 the reliability of the difference with the initial data), hematuria – to 26.38±1.43 cells in the field of vision (p<0.001), leukocyturia – to 22.04±0.88 cells in the field of vision (p<0.001), cylindruria – to 25.45±0.79 cylinders in the field of view (p<0.001). Against the background of a decrease in proteinuria and diuretic therapy, there was a decrease in the specific density of urine by 0.73% (up to 1014.15 ± 0.45g/l, reliability with baseline data - p <0.001).

Rivaroxaban is an effective oral anticoagulant, the long–term use of which as part of the basic therapy of patients with CGN is safe, well tolerated and pathogenetically justified. The inclusion of rivaroxaban in the basic therapy of patients with CGN is associated with the achievement of more favorable values of proteinuria, hematuria and leukocyturia by the end of the 3rd month of therapy.